🇺🇸 FDA
Pipeline program

Pembrolizumab plus denosumab

ANZUP1601

Phase 2 small_molecule active

Quick answer

Pembrolizumab plus denosumab for Renal Cell Carcinoma, Clear Cell is a Phase 2 program (small_molecule) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Zealand Pharma A/S
Indication
Renal Cell Carcinoma, Clear Cell
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials